scholarly journals A rare ovarian tumour, struma ovarii

Author(s):  
Sindhura Inkollu ◽  
Vandana Kanumury ◽  
Murmu Dasharatha ◽  
Padmaja Adusumilli
Keyword(s):  
2021 ◽  
Vol 14 (4) ◽  
pp. e240924
Author(s):  
Preethi Padmanaban ◽  
Eric Nylen ◽  
Kenneth Burman ◽  
Sabyasachi Sen

We report a case of 34-year-old clinically asymptomatic woman who had been followed for 6 years for hyperthyroidism with thyroid stimulating hormone <0.006 uIU/mL, free T4 1.98 ng/mL, free T3 5.3 pg/mL, elevated thyroid stimulating immunoglobulin 1.70 IU/L, thyroid peroxidase antibody 38 IU/mL and thyroglobulin antibody 9.3 IU/mL. Radioiodine thyroid scan showed minimal uptake in both thyroid lobes (24-hour uptake was 0.3%). She subsequently underwent evaluation for lower abdominal pain and menstrual irregularities, which revealed a large left ovarian cyst measuring 15.9 cm × 10.8 cm × 13.2 cm and right-sided ovarian cyst measuring 2.7 cm × 3.3 cm × 3.5 cm. Laparoscopic bilateral ovarian cystectomy was performed and the final pathology revealed struma ovarii of the left ovarian cyst with the entire ovarian tumour made up of benign thyroid tissue. Thyroid function tests performed 3 months after surgical removal of struma ovarii showed euthyroidism. We present a rare case with detailed laboratory and immunological data before and after ovarian extirpation with resolution of hyperthyroidism associated with functional struma ovarii.


2015 ◽  
Vol 56 (01) ◽  
pp. 35-39 ◽  
Author(s):  
J Wee ◽  
X Li ◽  
B Chern ◽  
I Chua
Keyword(s):  

Author(s):  
M L Gild ◽  
L Heath ◽  
J Y Paik ◽  
R J Clifton-Bligh ◽  
B G Robinson

Summary Struma ovarii is a rare, usually benign ovarian tumour with malignancy occurring in <5% of cases. Metastases, particularly seeding to bone, are extremely rare. Presentation is variable but often features local pain and/or ascites and hyperthyroidism may occur. It is not established how to best treat and follow patients with extensive disease. Case reports of radioiodine (I131) ablative therapy following thyroidectomy have shown reduced recurrence. We describe the case of a 33-year-old woman who presented with bone pain and was diagnosed with skeletal metastases with features of follicular thyroid carcinoma. However, thyroid pathology was benign. She recalled that 5 years prior, an ovarian teratoma was excised, classified at that time as a dermoid cyst. Retrospective review of this pathology confirmed struma ovarii without obvious malignant features. The patient was found to have widespread metastases to bone and viscera and her thyroglobulin was >3000 µg/L following recombinant TSH administration prior to her first dose of I131. At 25 months following radioiodine treatment, she is in remission with an undetectable thyroglobulin and clear I131 surveillance scans. This case demonstrates an unusual presentation of malignant struma ovarii together with challenges of predicting metastatic disease, and demonstrates a successful radioiodine regimen inducing remission. Learning points: Malignant transformation of struma ovarii (MSO) is extremely rare and even rarer are metastatic deposits in bone and viscera. MSO can be difficult to predict by initial ovarian pathology, analogous to the difficulty in some cases of differentiating between follicular thyroid adenoma and carcinoma. No consensus exists on the management for post operative treatment of MSO; however, in this case, three doses of 6Gbq radioiodine therapy over a short time period eliminated metastases to viscera and bone. Patients should continue to have TSH suppression for ~5 years. Monitoring thyroglobulin levels can predict recurrence.


2019 ◽  
Vol 25 ◽  
pp. 310-311
Author(s):  
Safa Ibrahim ◽  
Geeti Sharma ◽  
Biswaraj Tharu ◽  
Manivel Eswaran

2018 ◽  
Author(s):  
N Seegers ◽  
S Buchholz ◽  
S Seitz ◽  
A Teoman ◽  
D Hollemann ◽  
...  
Keyword(s):  

2018 ◽  
Author(s):  
N Seegers ◽  
S Buchholz ◽  
S Seitz ◽  
A Teomann ◽  
D Hollemann ◽  
...  
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document